Early 18ffluorodeoxyglucose positron emission tomographybased response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: A children's oncology group report

Peter D. Cole, Kathleen M. McCarten, Richard A. Drachtman, Pedro De Alarcon, Lu Chen, Tanya M. Trippett, Cindy L. Schwartz

Research output: Contribution to journalArticle

1 Scopus citations


The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.

Original languageEnglish (US)
Pages (from-to)650-657
Number of pages8
JournalPediatric Hematology and Oncology
Issue number8
Publication statusPublished - Oct 18 2010



  • Gemcitabine
  • Hodgkin disease
  • Phase 2 trial
  • Positron emission tomography
  • Treatment response
  • Vinorelbine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this